High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.
COVID-19
Ectonucleotidase
Immune system
Purinergic system
Journal
Journal of molecular medicine (Berlin, Germany)
ISSN: 1432-1440
Titre abrégé: J Mol Med (Berl)
Pays: Germany
ID NLM: 9504370
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
02
12
2021
accepted:
23
02
2022
revised:
21
02
2022
pubmed:
7
3
2022
medline:
2
4
2022
entrez:
6
3
2022
Statut:
ppublish
Résumé
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has significantly impacted the world and has driven many researchers into the pathophysiology of COVID-19. In the findings, there is a close association between purinergic signaling and the immune response. Then, this study aimed to evaluate alterations in the purinergic signaling in COVID-19 patients according to range severity. We divided the COVID-19 patients into moderate and severe cases following the guideless of NIH and WHO, together with clinical characteristics. The blood samples were collected to obtain PBMCs and platelets. We analyzed the ectonucleotidase activities through ATP, ADP, AMP, Ado hydrolysis, E-NTPDase1 (CD39), and 5'-NT (CD73) expression by flow cytometry in total leukocytes. The extracellular ATP was measured by bioluminescence, and cytokines were analyzed by flow cytometry. We observed a decrease in ATP hydrolysis and increased AMP hydrolysis in PBMCs for both groups. In severe cases, ATP hydrolysis was raised for the platelets, while ADP and AMP hydrolysis have risen significantly in both groups. Additionally, there was a significant increase in ADP hydrolysis in severe cases compared to moderate cases. In addition, we observed an increase in the ADA activity in platelets of moderate patients. Moderate and severe cases showed increased expression of CD39 and CD73 in total leukocytes. To finalize the purinergic signaling, extracellular ATP was increased in both groups. Furthermore, there was an increase in IL-2, IL-6, IL-10, and IL-17 in moderate and severe groups. Thus, for the first time, our findings confirm the changes in purinergic signaling and immune response in COVID-19, in addition to making it more evident that the severity range directly impacts these changes. Therefore, the therapeutic potential of the purinergic system must be highlighted and studied as a possible target for the treatment of SARS-CoV-2 disease. KEY MESSAGES: COVID-19 patients exhibit alterations in purinergic system and immune response. High levels of extracellular ATP lead to different inflammatory responses. CD39 and CD73 expression were increased in COVID-19 patients. Cytokines IL-2, IL-6, IL-10, and IL-17 also were altered in these patients. The purinergic system may be a possibility target to SARS-CoV-2 treatments.
Identifiants
pubmed: 35249135
doi: 10.1007/s00109-022-02185-4
pii: 10.1007/s00109-022-02185-4
pmc: PMC8898096
doi:
Substances chimiques
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
645-663Subventions
Organisme : CNPq
ID : 404256/2021-0
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Thromb Res. 2020 Jul;191:148-150
pubmed: 32381264
Mol Cell Biochem. 2013 Feb;374(1-2):137-48
pubmed: 23180243
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
Trends Mol Med. 2013 Jun;19(6):355-67
pubmed: 23601906
Biomed Pharmacother. 2021 May;137:111273
pubmed: 33524787
Trends Immunol. 2016 Jul;37(7):427-439
pubmed: 27236363
Mol Psychiatry. 2021 Apr;26(4):1044-1059
pubmed: 33328588
Thromb Res. 2003 Feb 15;109(4):189-94
pubmed: 12757773
PLoS One. 2012;7(7):e40829
pubmed: 22792409
Sci Immunol. 2018 Jul 6;3(25):
pubmed: 29980618
Front Immunol. 2021 Mar 18;12:613070
pubmed: 33815368
Mediators Inflamm. 2019 May 7;2019:4651627
pubmed: 31205451
Am J Physiol Cell Physiol. 2020 May 1;318(5):C832-C835
pubmed: 32159362
Purinergic Signal. 2013 Sep;9(3):307-24
pubmed: 23546842
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Clin Cancer Res. 2019 Feb 15;25(4):1318-1330
pubmed: 30420446
Mil Med Res. 2020 Mar 13;7(1):11
pubmed: 32169119
Med Oncol. 2019 Aug 2;36(9):78
pubmed: 31375946
Purinergic Signal. 2014 Dec;10(4):529-64
pubmed: 25352330
Purinergic Signal. 2012 Sep;8(3):437-502
pubmed: 22555564
Cell Signal. 2019 Jul;59:122-130
pubmed: 30926387
Cytometry B Clin Cytom. 2012 Jul;82(4):238-44
pubmed: 22539222
Br J Pharmacol. 2020 Nov;177(21):4990-4994
pubmed: 32441783
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
J Leukoc Biol. 2020 Jul;108(1):17-41
pubmed: 32534467
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Neurol Neurochir Pol. 2019;53(4):258-264
pubmed: 31343071
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Int J Obes (Lond). 2020 Sep;44(9):1832-1837
pubmed: 32712623
Acta Trop. 2010 Sep;115(3):262-9
pubmed: 20399737
Semin Immunol. 2019 Aug;44:101335
pubmed: 31734129
J Trop Med. 2012;2012:650874
pubmed: 22007242
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130
pubmed: 32475230
Int J Mol Sci. 2020 May 14;21(10):
pubmed: 32423094
Biotechniques. 2001 Aug;31(2):420-5
pubmed: 11515379
J Immunol. 2010 Jul 1;185(1):134-43
pubmed: 20498355
J Endocrinol Invest. 2021 May;44(5):951-956
pubmed: 32936429
Arch Pathol Lab Med. 2016 Apr;140(4):345-50
pubmed: 27028393
Scand J Clin Lab Invest Suppl. 1968;97:77-89
pubmed: 4179068
Pharmacol Res. 2017 May;119:36-47
pubmed: 28131875
BMC Infect Dis. 2020 Dec 21;20(1):963
pubmed: 33349241
Mol Cell Biochem. 2021 Aug;476(8):2891-2898
pubmed: 33740184
J Virol. 2011 Feb;85(3):1287-97
pubmed: 21047964
Platelets. 1996;7(4):225-30
pubmed: 21043691
Biofactors. 2007;31(2):77-98
pubmed: 18806312
J Allergy Clin Immunol. 2020 Sep;146(3):518-534.e1
pubmed: 32896310
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2097-103
pubmed: 22772752
Natl Sci Rev. 2020 Jun;7(6):1003-1011
pubmed: 34676126
Int J Mol Sci. 2019 Nov 03;20(21):
pubmed: 31684173
Front Pharmacol. 2019 Jun 13;10:612
pubmed: 31249523
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Nat Rev Immunol. 2010 Jul;10(7):514-26
pubmed: 20577268
Blood Cells Mol Dis. 2006 Mar-Apr;36(2):217-22
pubmed: 16476557
Sci Signal. 2019 Oct 29;12(605):
pubmed: 31662487
Int Rev Cytol. 2004;240:31-304
pubmed: 15548415
Purinergic Signal. 2016 Sep;12(3):439-51
pubmed: 27020575
EMBO J. 2014 Jun 17;33(12):1354-64
pubmed: 24843045
Purinergic Signal. 2018 Mar;14(1):1-18
pubmed: 29164451
Signal Transduct Target Ther. 2020 May 29;5(1):84
pubmed: 32467561
Cell Death Dis. 2020 Jun 8;11(6):429
pubmed: 32513989
J Biol Chem. 2010 Mar 5;285(10):7176-86
pubmed: 19858205
Lancet. 2014 Mar 15;383(9921):999-1008
pubmed: 24084292
J Immunol Res. 2020 Dec 1;2020:8632048
pubmed: 33299899
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
BMC Biol. 2020 Nov 26;18(1):182
pubmed: 33243234
J Virol. 2014 Aug;88(15):8479-89
pubmed: 24829345
Cytometry A. 2016 Jun;89(6):543-64
pubmed: 27144459
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Bull Exp Biol Med. 2018 Mar;164(5):609-611
pubmed: 29577202
Nat Commun. 2018 Dec 21;9(1):5457
pubmed: 30575716
Brain Neurosci Adv. 2018 Dec 6;2:2398212818817494
pubmed: 32166165
Biochim Biophys Acta. 2008 May;1783(5):673-94
pubmed: 18302942
Biochem Pharmacol. 2014 Apr 15;88(4):594-604
pubmed: 24445162
J Neuroimmune Pharmacol. 2021 Mar;16(1):48-58
pubmed: 33462776
J Neuroimmune Pharmacol. 2019 Jun;14(2):263-277
pubmed: 30353422
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Annu Rev Microbiol. 2019 Sep 8;73:529-557
pubmed: 31226023
Cytometry A. 2021 Jun 14;:
pubmed: 34125495
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Immunol. 2017 Aug 15;199(4):1372-1381
pubmed: 28687662
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Front Immunol. 2019 Oct 17;10:2465
pubmed: 31681335
Purinergic Signal. 2021 Sep;17(3):399-410
pubmed: 33970408
Cells. 2020 Jul 22;9(8):
pubmed: 32707842
Purinergic Signal. 2016 Mar;12(1):59-67
pubmed: 26739702
Front Pharmacol. 2020 Nov 26;11:594487
pubmed: 33324223
Nat Rev Neurol. 2020 Jul;16(7):347-348
pubmed: 32444648
Scand J Immunol. 2021 Feb;93(2):e12960
pubmed: 32797724
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
J Neuroimmune Pharmacol. 2020 Sep;15(3):359-386
pubmed: 32696264
Novartis Found Symp. 2006;276:113-28; discussion 128-30, 233-7, 275-81
pubmed: 16805426
J Immunol Res. 2018 Aug 12;2018:4892473
pubmed: 30159340